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Ventricular tachycardia (VT) is common in patients with
advanced heart failure, and medical therapy alone may have
limited success. Implantable cardioverter deﬁbrillators
(ICDs) have been widely accepted as standard of care for
VT management and prevention of sudden cardiac death.
However, this therapy does not in itself reduce episodes of
clinical VT. For patients who do not respond well to medical
therapy, percutaneous catheter ablation has been shown to
reduce episodes of recurrent VT.1 However, patients under-
going catheter ablation with a severely decreased left
ventricular ejection fraction (LVEF) may experience hemo-
dynamic instability during the ablation procedure, requiring
external hemodynamic support. One type of external hemo-
dynamic support is a temporary percutaneous ventricular
assist device (PVAD), which has been used to maintain
perfusion enabling the electrophysiologist to perform long
and complex procedures under more stable conditions.2
More speciﬁcally, the TandemHeart (TH) PVAD (Cardia-
cAssist, Pittsburgh, PA) has been shown to provide adequate
circulatory support during high-risk cardiac procedures.3
In typical catheter ablation procedures, the catheter is
manually guided by the physician. The Stereotaxis magnetic
navigation (SMN; St. Louis, MO) system utilizes 2 magnetic
platforms, one on each side of the patient, to remotely guideKEYWORDS Electromagnetic interference; Heart failure; Hemodynamic
instability; Magnetic navigation; Ventricular tachycardia
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been utilized by many centers for VT ablation.4 However,
it is not well established whether the SMN technology will
exhibit electromagnetic interference (EMI) when used
simultaneously with a PVAD. In this case study, we describe
the combined use of SMN and the TH PVAD on a patient
with severe cardiomyopathy and VT undergoing catheter
ablation, which to our knowledge had not been previously
performed in the United States at that time.
Case report
A 69-year-old male exhibited symptoms of dizziness and
lightheadedness before being shocked 7 times by his ICD
and was admitted to an outside hospital. The patient had a
known history of chronic heart failure from ischemic
cardiomyopathy dating back to 1996, when he was diag-
nosed with coronary artery disease and underwent multi-
vessel bypass grafting. Upon his admission to an outside
hospital, it was conﬁrmed that the device had shocked the
patient appropriately for VT, and he was started on mex-
iletine and ranolazine in addition to previously prescribed
sotalol. He underwent a left heart catheterization and
selective coronary angiogram demonstrating severe deterio-
ration of the LVEF to 12%, as well as severe occlusive
coronary disease without targets for revascularization.
He was transferred to our center, and upon evaluation, it
was recommended that a cardiac ablation procedure be
performed.
The SMN technique was determined to be the most
effective method to assist in the ablation procedure. How-
ever, because of the patient’s low ejection fraction, there was
signiﬁcant concern about the patient’s hemodynamic stabil-
ity in the setting of anesthesia and prolonged procedural
time. Based on this concern, the decision was made to use the
TH PVAD. At the time, it was unknown whether the TH
PVAD ﬂow would be interrupted or if the wire-wound
inﬂow and outﬂow cannulas would be displaced by the
strong magnetic ﬁeld (0.1 T) of the SMN machinery. Prior to
the procedure, a mock trial of the TH PVAD with the SMN
magnets was completed in the catheterization laboratory topen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.08.006
KEY TEACHING POINTS
 Stereotaxis magnetic navigation technology
provides an alternative to manually advanced
catheter ablation procedures by minimizing
ﬂuoroscopy exposure times for the operator and
offering more precise navigation.
 The TandemHeart percutaneous ventricular assist
device may allow for safe and effective
management of ventricular tachycardia in patients
with severe cardiomyopathy and hemodynamic
compromise.
 The TandemHeart percutaneous ventricular assist
device did not display any signs of electromagnetic
interference in the vicinity of the magnetic
navigation technology.
15Miller et al TandemHeart Support with Stereotaxis Ablationobserve any abnormal function. The mock trial included
placing the TH PVAD at distances of 3 ft (0.91 m) and 6 ft
(1.83 m). At each distance, the speed was adjusted to 2000
and 5000 rpm. When the 2 distances were compared at the
same speed, there was no signiﬁcant change in ﬂow for the
device. The cannulas were also advanced near the SMN
magnets to determine whether there would be signiﬁcant
interference. No interaction was observed, and it was
determined that there were no predictable risks involved
while using the PVAD and SMN simultaneously.
The patient was intubated and placed under general
anesthesia. After the induction of anesthesia at 8:30 AM,
the mean arterial pressure (MAP) rapidly dropped from 103
mm Hg (preanesthesia) to 50 mm Hg and the epinephrine
dosage was increased from 0.05 µg/kg/min to 0.2 µg/kg/min
to maintain reasonable perfusion. Percutaneous femoral
transseptal access was performed under the guidance of
ﬂuoroscopy and intracardiac echocardiography. A double-
wire technique was used to advance both an 8.5F Mullins
transseptal sheath to be used for mapping and ablation and a
PVAD transseptal uptake cannula (21F) into the left atrium.
The TH PVAD return cannula was placed via percutaneous
femoral access per the usual protocol. The PVADwas started
at 9:45 AM, and it provided, on average, 2.0 L/min ﬂow at a
speed of 5000 rpm. At this point, the hemodynamics
improved (MAP of 75 mm Hg), and a lower dosage of
epinephrine was needed (decreased to 0.04µg/kg/min)
throughout the remainder of the procedure.
A stable MAP was maintained while using the PVAD,
which allowed for detailed mapping and ablation using
SMN. Substrate mapping of the left ventricle revealed anextremely large apical aneurysmal scar extending up the
anterior wall and along the inferior wall and septum. More
than 8 different VT morphologies were identiﬁed with brief
induction, and extensive ablation was performed with an
emphasis on substrate modiﬁcation (Figure 1). At the end of
the 7-hour procedure, it proved difﬁcult to induce VT with
triple extrastimuli. The patient was successfully weaned
from the TH PVAD, which was removed in the electro-
physiology laboratory before extubation. A total of 11.4
minutes of ﬂuoroscopy was utilized for the entire procedure.
The patient tolerated the procedure well, and there were no
clinically evident peripheral vascular complications. Clinical
follow-up has shown the patient to be free of ventricular
arrhythmias for more than 18 months.Discussion
Stable hemodynamic support for this critically ill patient was
successfully provided using the TH PVAD while minimizing
the need for pharmacologic support within the SMN environ-
ment. MAP values were maintained in the presence of
extensive VT mapping and ablation, including several
episodes of sustained VT. In our view, the presence of the
TH PVAD facilitated the weaning of epinephrine and
mitigated the signiﬁcant risk of hemodynamic collapse in
this critically ill patient.
A primary concern when using SMN in conjunction with
other technologies is the potential for EMI. There are 2
different interactions that are generally a concern: the
interaction between the PVAD on the electro anatomic
mapping system and the interaction between the SMN
system and the PVAD motor. The interaction between the
PVAD and the mapping system has been observed by
Vaidya et. al.,4 who looked at the EMI produced when
magnet-based electroanatomic mapping was performed in
close proximity to the PVAD Impella 2.5 (Abiomed,
Danvers, MA). They found that severe EMI was observed
using Carto3 (Biosense Webster, Diamond Bar, CA) for
9.4% of all points attempted at the maximum performance
level (P8).5 The lack of EMI observed in our case study for
both types of interactions is likely due to the location of the
pump and drive mechanics. The TH PVAD motor is located
externally, in this case near the patient’s leg, in contrast to the
Impella motor, which is located internally near the left
ventricular outﬂow tract. In order to conﬁrm these ﬁndings,
a multicenter investigation of PVAD-assisted cardiac abla-
tions with multiple types of PVAD with SMN mapping
should be considered. Further study would yield important
results concerning the outcomes of this treatment option,
verify the lack of EMI observed in this case study, and
Figure 1 Cardiac isochronal map of the left ventricle. Both the A: left anterior oblique (LAO) view and B: right anterior oblique (RAO) view of the patient’s
heart demonstrate extensive ablation performed during the procedure
Heart Rhythm Case Reports, Vol 2, No 1, January 201616establish this approach as a reasonable option for this
difﬁcult clinical circumstance.
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